Biolase treatment patented

Irvine, CA-The U.S. Patent and Trademark Office has issued Biolase Technology two new patents covering the use of its laser technologies for treating various conditions of the eye, including presbyopia.

The patent covers a new strategy for identifying optimal treatment zones for the reversal of the condition and also relates to the shape of the treatment laser beam and specific ablative patterns for treating presbyopia.

Biolase currently holds 11 issued and 22 pending U.S. and international patents in four patent families in the field of ophthalmology.

“These new patents significantly enhance our intellectual property position in ophthalmology, a market segment that we are aggressively pursuing,” said Federico Pignatelli, chairman and chief executive officer of Biolase. “I am very pleased with Biolase’s continued efforts and success in increasing and protecting its intellectual property portfolio.”

Dmitri Boutoussov, PhD, chief technology officer of Biolase, said, “One of our key strategic plans is to create a diversified and balanced intellectual property portfolio that can be used in various ways to stimulate further adoption of our lasers in dentistry and medicine. These new ophthalmic patents substantiate our success in doing so.”